Associations between insulin pump self-management and HbA1c in type 1 diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 838 KB, PDF-dokument

Aims
Insulin pump self-management is important for glycaemic outcomes. We aimed to investigate associations between self-management factors and HbA1c.

Methods
Adult insulin pump users with type 1 diabetes (n = 770) completed an online questionnaire. The latest HbA1c and demographics were extracted from national registries. Associations between HbA1c and self-management (use of advanced features, timing of infusion set change, timing of meal bolus, data-upload and pump settings adjustments) were investigated using backward selected linear regression models.

Results
Of the 699 responders eligible for this study, 60% were women; the median age and diabetes duration were 49 and 25 years, respectively. Significant associations with HbA1c were found for changing infusion set every 0–4 days relative to 5–10 days (−5 mmol/mol (−0.4%), p = 0.003), and for never/rarely missing a bolus (−6 mmol/mol (−0.5%), p < 0.001) relative to often missing a bolus. Timing insulin 10–15 min before meal relative to after meal start was also associated with lower HbA1c (−3 mmol/mol (−0.3%), p = 0.023). Self-adjusting pump settings showed the strongest association with lower HbA1c (−6 mmol/mol (−0.6%), p < 0.001) relative to health care professionals doing all adjustments.

Conclusion
Self-adjusting insulin pump settings, optimal timing and few omissions of meal boluses, and timely change of infusion set are associated with lower HbA1c.
OriginalsprogEngelsk
Artikelnummere15068
TidsskriftDiabetic Medicine
Vol/bind40
Udgave nummer6
Antal sider10
ISSN0742-3071
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
K.R. owns shares in Novo Nordisk and has received speaker's honorarium from Medtronic. K.P.M. own shares in Novo Nordisk. H.U.A. owns shares in Novo Nordisk, has served on advisory boards for Novo Nordisk, Abbott, Sanofi and Astra Zeneca, and has received lecture fees from Nordic Infucare. E.H. serves as an adviser to Abbott and Novo Nordisk and owns shares in Novo Nordisk. U.P. reports advisory board attendance for Novo Nordisk, Sanofi Aventis, has received speaker's honorarium from Novo Nordisk, Sanofi Aventis, and has received research grants from Novo Nordisk. S.S. has received lecture fees from Novo Nordisk and is an employee of Novo Nordisk A/S since May 1st, 2022. K.N. serves as an adviser to Medtronic, Abbott, Convatec and Novo Nordisk. She owns shares in Novo Nordisk, has received research grants to her institution from Novo Nordisk, Medtronic, Dexcom, Zealand Pharma and Roche Diabetes Care, and has received lecture fees from Medtronic, Roche Diabetes Care, Rubin Medical, Sanofi, Novo Nordisk, Zealand Pharma, and Bayer AG.

Publisher Copyright:
© 2023 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.

ID: 365814790